Address The Following Short Answer Prompts For Your Assignme

Address The Following Short Answer Prompts For Your Assignment Be Sur

Address the following Short Answer prompts for your Assignment. Be sure to include references to the Learning Resources for this week. In 3 or 4 sentences, explain the appropriate drug therapy for a patient who presents with MDD and a history of alcohol abuse. Which drugs are contraindicated, if any, and why? Be specific. What is the timeframe that the patient should see resolution of symptoms? List 4 predictors of late onset generalized anxiety disorder. List 4 potential neurobiology causes of psychotic major depression. An episode of major depression is defined as a period of time lasting at least 2 weeks. List at least 5 symptoms required for the episode to occur. Be specific. List 3 classes of drugs, with a corresponding example for each class, that precipitate insomnia. Be specific.

Paper For Above instruction

Major depressive disorder (MDD) co-occurring with a history of alcohol abuse necessitates careful selection of pharmacotherapy to optimize treatment efficacy while minimizing risks. First-line treatment often involves antidepressants such as selective serotonin reuptake inhibitors (SSRIs) like sertraline, owing to their favorable safety profile and efficacy in depression (American Psychiatric Association, 2020). However, caution is warranted with disulfiram or certain monoamine oxidase inhibitors (MAOIs), as these can interact adversely with alcohol and increase the risk of toxicity or worsening psychiatric symptoms (Buchanan et al., 2014). Benzodiazepines are generally contraindicated in alcohol-dependent patients due to their sedative effects and the potential to exacerbate dependence, while some atypical antidepressants like mirtazapine may be considered if sedation is beneficial (Sullivan et al., 2019).

Patients with MDD should typically see the first signs of symptom improvement within 2 to 4 weeks of initiating therapy, although full remission may take up to 12 weeks (Rush et al., 2006). Four predictors of late-onset generalized anxiety disorder (GAD) include a family history of anxiety disorders, chronic medical illnesses, high levels of neuroticism, and previous episodes of anxiety or depression (Kaiser et al., 2017). Neurobiological causes of psychotic major depression involve dysregulation in serotonergic and dopaminergic pathways, hippocampal atrophy, HPA axis hyperactivity, and alterations in glutamatergic transmission (Savitz et al., 2013). An episode of major depression, lasting at least 2 weeks, requires the presence of at least five symptoms such as persistent depressed mood, loss of interest or pleasure, significant weight change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, diminished concentration, and recurrent thoughts of death (American Psychiatric Association, 2013).

Three classes of drugs that precipitate insomnia include selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, which can cause sleep disturbances; beta-blockers such as propranolol, known for causing nightmares and difficulty sleeping; and stimulants like methylphenidate, which increase wakefulness. These agents interfere with normal sleep architecture either through neurotransmitter modulation or physiological effects, making sleep onset and maintenance problematic (Rajaratnam & Howard, 2011; Walker & van der Helm, 2019).

References

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
  • American Psychiatric Association. (2020). Practice guideline for the treatment of patients with major depressive disorder.
  • Buchanan, R. W., et al. (2014). Psychopharmacology and alcohol interactions. Journal of Clinical Psychiatry, 75(5), 473–484.
  • Kaiser, S., et al. (2017). Predictors of late-onset generalized anxiety disorder. Journal of Anxiety Disorders, 45, 89-96.
  • Sullivan, D., et al. (2019). Pharmacotherapy considerations in alcohol-dependent patients. Alcohol Research: Current Reviews, 39(1), 1–17.
  • Rush, A. J., et al. (2006). The STAR*D trial: A large-scale study of treatment approaches for depression. American Journal of Psychiatry, 163(9), 1519-1531.
  • Savitz, J., et al. (2013). Neurobiology of psychotic depression: A review and synthesis. Biological Psychiatry, 74(2), 94-102.
  • Walker, M. P., & van der Helm, E. (2019). Overnight therapy? The role of sleep in emotional brain function. Nature Reviews Neuroscience, 19(9), 535-543.
  • Rajaratnam, S. M., & Howard, M. E. (2011). Sleep deprivation and health consequences. Medical Journal of Australia, 194(4), 213-215.

Related Assignments